US EditionAvenzo begins Phase I/II trial of CDK4 selective inhibitor for breast cancer
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Avenzo begins Phase I/II trial of CDK4 selective inhibitor for breast cancer
Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast cancer.The post Avenzo begins Phase I/II trial of CDK4 selective inhibitor for breast cancer appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
